Image Source : Indian Chemical News
Sigachi Industries Ltd has officially initiated its most ambitious manufacturing expansion to date—a 12,000 metric tonnes per annum (MTPA) Microcrystalline Cellulose (MCC) project at the Dahej Special Economic Zone (SEZ) in Bharuch, Gujarat. With environmental clearance secured from the Gujarat State Environment Impact Assessment Authority (SEIAA), the greenfield facility is poised to redefine India’s role in the global pharmaceutical and nutraceutical supply chain.
Key Developments and Strategic Highlights
- Sigachi Industries receives SEIAA environmental clearance for Dahej SEZ plant
- New facility to produce 3,120 MT/month of MCC and specialty excipients
- Total annual capacity: 12,000 MTPA
- Products to serve pharmaceutical, nutraceutical, and food-grade markets
- Facility designed to meet international regulatory standards
- Strategic location within SEZ to boost exports and operational agility
Project Scope and Technical Details
The Dahej SEZ facility will manufacture a wide portfolio of cellulose and starch-based excipients, including MCC—a critical ingredient used in tablet formulation across pharmaceutical and nutraceutical industries.
- Installed capacity: 3,120 MT/month
- Product categories: MCC, starch-based excipients, and high-value functional ingredients
- Target markets: North America, Europe, Asia-Pacific
- Compliance: Designed to meet stringent regulatory norms for regulated and semi-regulated markets
This capacity expansion marks a pivotal shift in Sigachi’s manufacturing capabilities, enabling it to meet rising global demand while maintaining quality and scalability.
Why Dahej SEZ Matters
The choice of Dahej SEZ is strategic. Located in Bharuch, Gujarat, the zone offers logistical advantages, export incentives, and regulatory support that align with Sigachi’s global ambitions.
- SEZ benefits: Tax incentives, simplified compliance, export facilitation
- Proximity to ports and industrial corridors
- Enhanced supply chain resilience and reduced lead times
- Integration with India’s “Make in India” and pharma export push
The facility’s location is expected to improve Sigachi’s responsiveness to international clients and reduce dependency on external suppliers.
Leadership Vision and Industry Impact
Amit Raj Sinha, Managing Director and CEO of Sigachi Industries, emphasized that the Dahej project is more than a capacity addition—it’s a strategic enabler of the company’s next growth cycle.
- Strengthens Sigachi’s integrated manufacturing ecosystem
- Enhances supply resilience for global customers
- Positions Sigachi as a key player in high-margin excipient segments
- Supports India’s ambition to become a global pharma manufacturing hub
The project is expected to create hundreds of skilled jobs and stimulate ancillary industries in the region.
Global Expansion and Market Positioning
Sigachi’s Dahej facility is designed to support its international expansion goals, particularly in regulated markets where quality and compliance are paramount.
- MCC demand is rising due to growth in oral solid dosage forms
- Nutraceuticals and functional foods are driving excipient innovation
- Sigachi aims to capture market share in high-growth regions
- The facility will serve as a benchmark for future expansions
By aligning with global trends and regulatory expectations, Sigachi is positioning itself as a preferred supplier for multinational pharmaceutical companies.
Conclusion
Sigachi Industries’ 12,000 MTPA MCC project at Dahej SEZ is not just a manufacturing milestone—it’s a strategic leap toward global leadership in pharmaceutical excipients. With environmental clearance secured and construction underway, the company is set to transform its operational footprint and reinforce India’s standing in the global pharma supply chain.
Source: Global Flow Control, Indian Pharma Post, Projects Today
Advertisement
Advertisement
